echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > How digital can help pharmaceutical companies ride the waves as change takes place.

    How digital can help pharmaceutical companies ride the waves as change takes place.

    • Last Update: 2020-10-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "The past year has been very unusual, the world has changed dramatically, and the epidemic has brought great challenges," said Jack Ma, Alibaba's founder and director, at a large online conference in September.
    of all the great uncertainties today, one thing is certain: the trend towards digitalization has not changed.
    " at the same time, he pointed out that the biggest beneficiaries of the digitalization process is not Internet companies, but the use of the Internet to transform their own enterprises, the phrase for the vast number of medical enterprises after the outbreak, can not be more applicable.
    , according to incomplete statistics, in the first half of 2020, there were 37 investment and financing incidents in the domestic digital medical field, with a transaction value of more than 4 billion yuan.
    Of these, 11 financing amounted to RMB 100 million, accounting for about 31% of the total, according to the Arterial Net Eggshell Research Institute data, in foreign countries, the direction of digital medical health has accumulated more than 240 investment and financing incidents, the cumulative financing amount reached 39.2 billion yuan.
    Can be seen that under the catalysis of the epidemic, digital medical treatment has been ranked in the investment institutions directly bid for the "priority", but also under the influence of the epidemic, more and more pharmaceutical companies began to pay attention to digital transformation, data show that since this year, the major pharmaceutical companies in the digital construction of investment significantly increased, in 2019 digital-related costs accounted for more than 10% of the total investment costs of pharmaceutical companies accounted for 23%, and in March 2020, this figure quickly increased to 40%.
    change has already taken place.
    Digitization is imperative a drug from nothing to the hands of patients, probably after looking for targets, drug design synthesis and screening, preclinical trials, clinical trials, drug approval and marketing and other five stages, and this district five stages but let pharmaceutical companies take about decades, well-known multinational pharmaceutical company Roche has According to this set of data, it takes an average of 12 years from the initial laboratory research to the final placement to the sale of the drug cabinet, requiring an investment of Rmb6,614.5 million, 7,000,874 hours, 6,587 experiments, 423 researchers, and finally one drug.
    long and costly research and development cycle, the high risk has become a special label for the development of new drugs.
    On the other hand, in recent years, with the full implementation of generic consistent evaluation, the tightening of medical insurance charges, the adjustment of the medical insurance catalog into normal, multi-wheeled volume of procurement gradually landed, with gold sales of strict inspection and elimination of such measures, the profit margins of pharmaceutical companies are further compressed, facing more intense competition, the market pattern is being comprehensively remodeled.
    In particular, under the outbreak of new crown pneumonia, comprehensive isolation measures not only limit some pharmaceutical activities of pharmaceutical companies from the geographical space, but also disrupt their clinical research and development, marketing promotion and other past operational activities, under the overlay of the above-mentioned various backgrounds, how to reduce cost efficiency, compliance development, and multi-dimensional to meet the needs of the market, pharmaceutical companies to achieve digital production processes more and more strong demand.
    with the development of big data and artificial intelligence, digitalization can penetrate into the full life cycle of a drug.
    in the research and development phase, the core of digitalization is to improve efficiency.
    the main line of new drug research and development can be divided into pre-clinical experimental stage, clinical trial stage and registration declaration stage.
    digitalization of the research and development process is conducive to knowledge precipitation and experimental design records in the experimental phase, as well as coordination of communication and cooperation between different institutions in the clinical stage, and can also significantly reduce the time for registration declaration and audit.
    in the production stage, the core of digitalization is to achieve management standardization.
    the core of pharmaceutical production is to restrain the production personnel operation of the norms, compliance, in accordance with the standards and norms of production, on this basis as far as possible optimization.
    In the logistics and distribution stage, the core of digitalization lies in the realization of traceability, through acceptance, storage, sorting, distribution, monitoring and other aspects of the data, is conducive to eliminating human error and environmental conditions interference, so that the preservation of drugs, distribution can be automatically and strictly in accordance with the established optimization process standards and quality and safety management norms.
    in the marketing phase, the core of digitalization is efficient compliance, by matching different marketing scenarios, such as reaching doctors, completing academic education, increasing patient traffic, and managing patient compliance.
    " About three or four years ago, there were many pharmaceutical companies that chose to ignore the digitalization of the medical industry, whether it's the digitization of clinical research, the digitization of commercial marketing, or the digitization of expert visits and patient management, which some companies didn't pay attention to, and years have passed, and no one should continue to ignore digitalization.
    " at the first symposium of the CAHA Digital Medical Professional Committee held recently, Zhang Tianze, founder and chief executive officer of Zero-Jiang Technology, said in an interview with Medical Valley.
    pharmaceutical companies digital more and more pharmaceutical companies are fully involved in digitalization, especially some head pharmaceutical companies, but also spare no effort.
    At last year's Expo, M.D.A. reporters were invited to visit a clinical trial management SENSE digital platform, a "control tower" developed by Novartic over the years to manage global clinical trials, similar to the transportation hub's monitoring center, which monitors more than 500 drug clinical trials (phases I, II, III) in more than 70 countries around the world in real time and alerts the risk index of clinical trials.
    there is another company in the digital distribution of AstraZeneca, Medical Valley reporter from CAHA Digital Medical Professional Committee first symposium was informed that it is the world's first cloud-based digital platform to replace the traditional trial management system of large pharmaceutical companies.
    In particular, AstraZenecom has built a digital Internet infrastructure, such as using data-driven technology to plan clinical studies, can create research cost estimates in five minutes, select trial sites 70 percent faster than before, increase the diversity of trials, and ensure that the trial population is more representative of potential patients in the real world, a digital improvement in the clinical supply chain that saves more than $100 million and reduces trial waste by more than 40 percent, and builds the ability to trial in a matter of months.
    At the same time, AstraZenecom has redefined digital health by providing digital solutions that find that up to 70% of trial data can be collected remotely, including data from more than 100 wearable devices brought into patients' homes by care homes that will be evaluated as clinically effective products with effective patient experience to support their successful use in clinical trials.
    As a domestic CRO giant, drug Mingkangde is also vigorously involved in digitalization, it is understood that at this stage, pharmaceutical Mingkangde is committed to building a new ecological health care, mainly contains two aspects: pharmaceutical and treatment, pharmaceutical grasp is to improve the process, optimize resources, and treatment is based on real-world data to increase users and use scenarios, the two form a closed loop, to achieve a new model of medical research and development.
    At the same time, Pharmaceutical Mingkang is also focusing on digital transformation and digital innovation, which includes enabling digital operations that enable process tracking and optimization, resource scheduling and planning, empowering data users and federal data platform architecture, and in digital innovation, according to Therminconde Senior Vice President, Chief Data Officer Chen Zhigang, at the meeting, Pharmaceutical Mingkangde is considering integrating a digital clinical trial platform to help drug research and development.
    "We want the relevant data to be quickly applied on this platform and to be associated with other securely certified data."
    ," Chen zhigang said.
    If drug companies are running to digitalize and empower themselves with information technology, big data and AI, providers of information digital solutions such as Mindy Control are a powerful "foreign aid force" for pharmaceutical companies to upgrade their digital transformation.
    According to The Chairman of Mindu Wisdom Ge Yafei in an interview with Medical Valley, the company can provide pharmaceutical companies with a full life cycle digital management solution covering research and development, production and logistics, for pharmaceutical companies to establish a transparent system of full traceability, in the research and development side, Mingzhi control focus on the pre-clinical experimental stage and registration and declaration stage, to help pharmaceutical companies to establish a drug research and development life cycle management platform, improve the consistency of real data, and finally complete electronic declaration, core products including products such as CTD, PLM (PLM) At the production side, Ming-Chi-Control can provide pharmaceutical enterprises with systems such as the digital production execution system (MES/EBR) to realize the data electronic batch statistics, fault detection and diagnosis of the drug production process, quality control, etc.;
    has only just begun to improve the stage of digital penetration, but also to see that compared with Europe and the United States and other countries, the current digital transformation of domestic pharmaceutical companies is still in its infancy, to marketing, for example, according to Price water prices and tradeshoot consulting firms earlier published a survey of more than 150 pharmaceutical executives in Europe and the United States, 90% of pharmaceutical companies have been widely promoted or piloted Digital tools as one of the marketing channels to provide diseases, products, academic cutting-edge technology and medical education information and services, and in China, although there is no relevant local pharmaceutical companies survey data, but according to the domestic major pharmaceutical companies high sales costs, the use of digital marketing ratio estimates are only rare, thus, the domestic pharmaceutical companies digital transformation road, in fact, has just begun.
    " domestic pharmaceutical enterprises are still in the initial stage of digital transformation, mature model is relatively small.
    " Sanofi China medical department head Gu Chengming said, but many companies have realized the importance of digital transformation, is actively engaged in multi-channel exploration, such as digital clinical trial subject recruitment, marketing customer portraits accurate portrayal, and so on.
    Zhang Tianze said: "Digitalization in clinical diagnosis and treatment progress is relatively fast, but in drug research and development is slower, mainly because drug research and development is actually a very cautious process, this process has a large number of established decision-making habits and the formation of work organization and value relations, but also a mechanism network more traditional and intensive industry, it involves a lot of people's collaboration, a lot of links, which link wants to do digital alone is very difficult, must be done with upstream and downstream partners."
    " In addition, for those who have not yet dabbled in digital traditional pharmaceutical companies or have not yet carried out large-scale digital transformation of pharmaceutical companies, Zhang Tianze suggested: First, there must be a clear top-down strategy within the team, followed by the establishment of a relatively experienced team, so as to avoid as few detours as possible, less stepping on others stepped on the pit, and finally to find a reliable external partner to work together.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.